Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR3 | O14843 | 1/20 | 0.62 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.62 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.62 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.62 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.62 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.42 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.41 |
| ▸ | PPARG | P37231 | 7/20 | 0.41 |
| ▸ | PPARD | Q03181 | 7/20 | 0.41 |
| ▸ | PPARA | Q07869 | 7/20 | 0.41 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.41 |
| ▸ | TSHR | P16473 | 5/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | TLR2 | O60603 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | FABP4 | P15090 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.41 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Butyric Acid SCHEMBL834319 | 0.93 | FFAR3 (0.72) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| Butyric Acid SCHEMBL5477656 | 0.90 | FFAR3 (0.68) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| Butyric Acid SCHEMBL8517702 | 0.90 | FFAR3 (0.68) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| Butyric Acid SCHEMBL8712901 | 0.88 | FFAR3 (0.59) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| Butyric Acid SCHEMBL5904081 | 0.88 | FFAR3 (0.65) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| Butyric Acid SCHEMBL9486329 | 0.88 | FFAR3 (0.65) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| R-Chloropropionate SCHEMBL28240839 | 0.88 | FFAR3 (0.50) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| Butyric Acid SCHEMBL7952938 | 0.87 | FFAR3 (0.81) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| Butyric Acid SCHEMBL7947676 | 0.87 | FFAR3 (0.81) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| Butyric Acid SCHEMBL487253 | 0.87 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3682903-A1 | MODIFIED OLIGONUCLEOTIDES FOR TELOMERASE INHIBITION | GERON CORPORATION (US) | 2020-07-22 | — | — | EP | disclosed |
| EP-3342425-B1 | MODIFIED OLIGONUCLEOTIDES FOR TELOMERASE INHIBITION | GERON CORP (US) | 2019-12-18 | — | — | EP | disclosed |
| US-10196641-B2 | Modified oligonucleotides for telomerase inhibition | GERON CORPORATION (US) | 2019-02-05 | — | — | US | disclosed |
| EP-3342425-A1 | MODIFIED OLIGONUCLEOTIDES FOR TELOMERASE INHIBITION | GERON CORPORATION (US) | 2018-07-04 | — | — | EP | disclosed |
| EP-1667522-B1 | MODIFIED OLIGONUCLEOTIDES FOR TELOMERASE INHIBITION | GERON CORP (US) | 2018-01-17 | — | — | EP | disclosed |
| US-9657296-B2 | Modified oligonucleotides for telomerase inhibition | GERON CORPORATION (US) | 2017-05-23 | — | — | US | disclosed |
| US-20170130225-A1 | MODIFIED OLIGONUCLEOTIDES FOR TELOMERASE INHIBITION | GERON CORPORATION | 2017-05-11 | — | — | US | disclosed |
| US-9404112-B2 | Modified oligonucleotides for telomerase inhibition | GERON CORPORATION (US) | 2016-08-02 | — | — | US | disclosed |
| US-9388416-B2 | Modified oligonucleotides for telomerase inhibition | BIOPHARMA CREDIT PLC [COLLATERAL AGENT] (GB) | 2016-07-12 | — | — | US | disclosed |
| US-9388415-B2 | Modified oligonucleotides for telomerase inhibition | BIOPHARMA CREDIT PLC [COLLATERAL AGENT] (GB) | 2016-07-12 | — | — | US | disclosed |
| US-20130345181-A1 | PYRROLOPYRIDINEAMINO DERIVATIVES AS MPS1 INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2013-12-26 | — | — | US | disclosed |
| US-20130065950-A1 | MODIFIED OLIGONUCLEOTIDES FOR TELOMERASE INHIBITION | GERON CORPORATION | 2013-03-14 | — | — | US | disclosed |
| US-20120329858-A1 | MODIFIED OLIGONUCLEOTIDES FOR TELOMERASE INHIBITION | GERON CORPORATION | 2012-12-27 | — | — | US | disclosed |
| WO-2012123745-A1 | PYRROLOPYRIDINEAMINO DERIVATIVES AS MPS1 INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2012-09-20 | — | — | WO | disclosed |
| US-20120129918-A1 | MODIFIED OLIGONUCLEOTIDES FOR TELOMERASE INHIBITION | GERON CORPORATION | 2012-05-24 | — | — | US | disclosed |
| US-20090286853-A1 | MODIFIED OLIGONUCLEOTIDES FOR TELOMERASE INHIBITION | GERON CORPORATION | 2009-11-19 | — | — | US | disclosed |
| US-7494982-B2 | Modified oligonucleotides for telomerase inhibition | GERON CORPORATION (US) | 2009-02-24 | — | — | US | disclosed |
| EP-1667522-A2 | MODIFIED OLIGONUCLEOTIDES FOR TELOMERASE INHIBITION | Geron Corporation (US) | 2006-06-14 | — | — | EP | disclosed |
| US-20050113325-A1 | Modified oligonucleotides for telomerase inhibition | BIOPHARMA CREDIT PLC [COLLATERAL AGENT] (GB) | 2005-05-26 | — | — | US | disclosed |
| WO-2005023994-A2 | MODIFIED OLIGONUCLEOTIDES FOR TELOMERASE INHIBITION | GERON CORPORATION (US) | 2005-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130345181-A1 | PYRROLOPYRIDINEAMINO DERIVATIVES AS MPS1 INHIBITORS | BUB1B, BUB1, PPM1D | FFAR3 4808/4885HDAC3 2446/4885HDAC1 1431/4885 |
| US-20130065950-A1 | MODIFIED OLIGONUCLEOTIDES FOR TELOMERASE INHIBITION | TERT, TRDMT1, TERF2 | FFAR3 3742/4885HDAC3 1643/4885HDAC1 936/4885 |
| US-20120129918-A1 | MODIFIED OLIGONUCLEOTIDES FOR TELOMERASE INHIBITION | TERT, TRDMT1, TERF2 | FFAR3 3742/4885HDAC3 1643/4885HDAC1 936/4885 |
| US-20050113325-A1 | Modified oligonucleotides for telomerase inhibition | TERT, TRDMT1, TERF2 | FFAR3 3742/4885HDAC3 1643/4885HDAC1 936/4885 |
| US-10196641-B2 | Modified oligonucleotides for telomerase inhibition | TERT, TRDMT1, TERF2 | FFAR3 3742/4885HDAC3 1643/4885HDAC1 936/4885 |
| US-20090286853-A1 | MODIFIED OLIGONUCLEOTIDES FOR TELOMERASE INHIBITION | TERT, TRDMT1, TERF2 | FFAR3 3742/4885HDAC3 1643/4885HDAC1 936/4885 |
| US-20120329858-A1 | MODIFIED OLIGONUCLEOTIDES FOR TELOMERASE INHIBITION | TERT, TRDMT1, TERF2 | FFAR3 3742/4885HDAC3 1643/4885HDAC1 936/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.